In colorectal cancer, RUNX1 is a biomarker for the development of chemotherapy programs and it can activate the Hedgehog signaling pathway by up-regulating the expression of ABCG2, inducing resistance to 5-fluorouracil by colorectal tumor cells [15]. This evidence concerns the gene RUNX1 and colorectal cancer.